Goldman Sachs Maintains Neutral on Reliance Steel & Aluminum, Raises Price Target to $270
Goldman Sachs analyst Kate McShane maintains Reliance Steel & Aluminum (NYSE:RS) with a Neutral and raises the price target from $245 to $270.
Goldman Sachs Maintains Neutral on Invesco, Lowers Price Target to $19
Goldman Sachs analyst Alexander Blostein maintains Invesco (NYSE:IVZ) with a Neutral and lowers the price target from $20 to $19.
Goldman Sachs Maintains Buy on General Electric, Raises Price Target to $96
Goldman Sachs analyst Joe Ritchie maintains General Electric (NYSE:GE) with a Buy and raises the price target from $84 to $96.
Goldman Sachs Maintains Buy on Fulcrum Therapeutics, Lowers Price Target to $9
Goldman Sachs analyst Madhu Kumar maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and lowers the price target from $17 to $9.
JMP Securities Reiterates Market Outperform on PennantPark Floating Rate, Maintains $12 Price Target
JMP Securities analyst Kevin Fitzsimmons reiterates PennantPark Floating Rate (NYSE:PFLT) with a Market Outperform and maintains $12 price target.
Wedbush Reiterates Outperform on Cognizant Tech Solns, Maintains $75 Price Target
Wedbush analyst Moshe Katri reiterates Cognizant Tech Solns (NASDAQ:CTSH) with a Outperform and maintains $75 price target.
JMP Securities Reiterates Market Outperform on Marketwise, Maintains $6 Price Target
JMP Securities analyst Devin Ryan reiterates Marketwise (NASDAQ:MKTW) with a Market Outperform and maintains $6 price target.
JMP Securities Reiterates Market Outperform on LPL Finl Hldgs, Maintains $290 Price Target
JMP Securities analyst Devin Ryan reiterates LPL Finl Hldgs (NASDAQ:LPLA) with a Market Outperform and maintains $290 price target.
Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target
Mizuho analyst Uy Ear reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and maintains $19 price target.
What 13 Analyst Ratings Have To Say About Moderna
Over the past 3 months, 13 analysts have published their opinion on Moderna (NASDAQ:MRNA) stock. These analysts are…